SCHEMBL716374

SCHEMBL716374

COc1ccc2oc(C(=O)C3CCCCC3)c(Br)c2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.65
KDM4E B2RXH2 8/20 0.65
NPC1 O15118 7/20 0.65
SMN1; SMN2 Q16637 7/20 0.65
ALDH1A1 P00352 6/20 0.65
HSD17B10 Q99714 5/20 0.65
HPGD P15428 4/20 0.65
MAPT P10636 4/20 0.65
POLB P06746 3/20 0.47
TP53 P04637 2/20 0.47
HTT P42858 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CYP1A2 P05177 2/20 0.47
RECQL P46063 1/20 0.47
LMNA P02545 1/20 0.45
MTNR1A P48039 2/20 0.44
MTNR1B P49286 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6228609 0.81 KDM4E (0.61) RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1
SCHEMBL3375173 0.79 KDM4E (0.58) RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1
SCHEMBL7377144 0.74 KDM4E (0.53) RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1
SCHEMBL717995 0.74 RAB9A (0.56) RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1
SCHEMBL718439 0.73 KDM4E (0.50) RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1
SCHEMBL717615 0.73 RAB9A (0.65) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL718236 0.73 NPC1 (0.52) RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1
SCHEMBL719030 0.73 RAB9A (0.47) RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1
SCHEMBL16163091 0.72 POLB (0.61) RAB9AKDM4ENPC1ALDH1A1HPGD
SCHEMBL4766395 0.72 RAB9A (0.55) RAB9AKDM4ENPC1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RAB9A 2454/4885KDM4E 1907/4885NPC1 902/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RAB9A 2454/4885KDM4E 1907/4885NPC1 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.